New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
05:29 EDTABBVAbbVie presents results from multi-country ALIGN study
AbbVie announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases, or IMIDs, adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy. Furthermore, patients who were "accepting" toward their medication were more often adherent, compared to patients who were "ambivalent" toward their medication, as estimated from their responses to validated questionnaires. Results showed adherence to treatment, as determined by MMAS-4 scores, was generally higher in patients treated with TNF inhibitors with or without conventional therapy compared to patients treated with conventional therapy. Across all treatment types, a higher percentage of "accepting" patients were adherent to treatment compared to "ambivalent" patients based on MMAS-4 analysis and combined BMQ scores.
News For ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 23, 2015
11:19 EDTABBVEnanta announces JAMA publication of AbbVie VIEKIRA PAK study results
Subscribe for More Information
11:04 EDTABBVAbbVie reports VIEKIRA PAK HPV/HIV co-infection study results published
Subscribe for More Information
February 20, 2015
10:33 EDTABBVBattleground update: AbbVie named top global pick at Jefferies
Subscribe for More Information
07:23 EDTABBVAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
February 19, 2015
12:13 EDTABBVAbbVie increases quarterly dividend 4% to 51c per share
Subscribe for More Information
February 17, 2015
18:06 EDTABBVPaulson & Co gives quarterly update on stakes
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use